New Psychedelic Therapy AKO004 Under Development by Akome

New Psychedelic Therapy AKO004 Under Development by Akome

301237

New Psychedelic Therapy AKO004 Under Development by Akome

A new psychedelic drug formulation called AKO004 is now under development by Akome Biotech, a wholly owned subsidiary of Core One Labs, as a potential treatment for Parkinson’s disease. The company has filed a provisional patent application for AKO004 with the U.S. Patent and Trademark Office. The AKO004 formulation comprises N, N-dimethyltryptamine, known as DMT, and a naturally occurring plant bioactive. According to the company, preliminary research suggests that AKO004 may play a neuroprotective role…

You must be logged in to read/download the full post.